9-Cycloheptylnonanoic acid | 164524-23-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 9-Cycloheptylnonanoic acid
• 英文别名: 9-cycloheptylnonanoic acid
• CAS: 164524-23-6
• 化学式: C₁₆H₃₀O₂
• 分子量: 254.413
• InChiKey: UQBKDOGXRBMFLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  9-Cycloheptylnonanoic acid 在 盐酸 、 5%-palladium/activated carbon 、 水 、 氢气 、 1-羟基苯并三唑 、 乙酸乙酯 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 3-(9-cycloheptyl-N-hydroxynonanamido)propanoic acid
  参考文献：
  名称：

  Identification of the KDM2/7 Histone Lysine Demethylase Subfamily Inhibitor and its Antiproliferative Activity

  摘要：

  Histone N-e-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. On the basis of the crystal structure of KDM7B, we designed and prepared a series of hydroxamate analogues bearing an alkyl chain. Enzyme assays revealed that compound 9 potently inhibits KDM2A, KDM7A, and KDM7B, with IC(50)s of 6.8, 0.2, and 1.2 mu M, respectively. While inhibitors of KDM4s did not show any effect on cancer cells tested, the KDM2/7-subfamily inhibitor 9 exerted antiproliferative activity, indicating the potential for KDM2/7 inhibitors as anticancer agents.

  DOI：

  10.1021/jm400624b
• 作为产物：
  描述：

  9-bromononanoic acid sodium salt 、 cycloheptyl magnesium bromide 在 dilithium tetrachlorocuprate 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.0h， 生成 9-Cycloheptylnonanoic acid
  参考文献：
  名称：

  Identification of the KDM2/7 Histone Lysine Demethylase Subfamily Inhibitor and its Antiproliferative Activity

  摘要：

  Histone N-e-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. On the basis of the crystal structure of KDM7B, we designed and prepared a series of hydroxamate analogues bearing an alkyl chain. Enzyme assays revealed that compound 9 potently inhibits KDM2A, KDM7A, and KDM7B, with IC(50)s of 6.8, 0.2, and 1.2 mu M, respectively. While inhibitors of KDM4s did not show any effect on cancer cells tested, the KDM2/7-subfamily inhibitor 9 exerted antiproliferative activity, indicating the potential for KDM2/7 inhibitors as anticancer agents.

  DOI：

  10.1021/jm400624b

文献信息

• Processes and host cells for genome, pathway, and biomolecular engineering
  申请人：enEvolv, Inc.

  公开号：US10370654B2

  公开（公告）日：2019-08-06

  The present disclosure provides compositions and methods for genomic engineering.

  本公开提供了基因组工程的组合物和方法。
• PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING
  申请人：enEvolv, Inc.

  公开号：EP3027754A1

  公开（公告）日：2016-06-08
• US9944925B2
  申请人：——

  公开号：US9944925B2

  公开（公告）日：2018-04-17
• [EN] PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING<br/>[FR] PROCÉDÉS ET CELLULES HÔTES POUR INGÉNIERIE BIOMOLÉCULAIRE, GÉNOMIQUE ET DE LA VOIE
  申请人：ENEVOLV INC

  公开号：WO2015017866A1

  公开（公告）日：2015-02-05

  The present disclosure provides compositions and methods for genomic engineering.
• Identification of the KDM2/7 Histone Lysine Demethylase Subfamily Inhibitor and its Antiproliferative Activity
  作者：Takayoshi Suzuki、Hiroki Ozasa、Yukihiro Itoh、Peng Zhan、Hideyuki Sawada、Koshiki Mino、Louise Walport、Rei Ohkubo、Akane Kawamura、Masato Yonezawa、Yuichi Tsukada、Anthony Tumber、Hidehiko Nakagawa、Makoto Hasegawa、Ryuzo Sasaki、Tamio Mizukami、Christopher J. Schofield、Naoki Miyata

  DOI：10.1021/jm400624b

  日期：2013.9.26

  Histone N-e-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. On the basis of the crystal structure of KDM7B, we designed and prepared a series of hydroxamate analogues bearing an alkyl chain. Enzyme assays revealed that compound 9 potently inhibits KDM2A, KDM7A, and KDM7B, with IC(50)s of 6.8, 0.2, and 1.2 mu M, respectively. While inhibitors of KDM4s did not show any effect on cancer cells tested, the KDM2/7-subfamily inhibitor 9 exerted antiproliferative activity, indicating the potential for KDM2/7 inhibitors as anticancer agents.